List view / Grid view
From exciting data on cell therapy and monoclonal antibodies, through to new regulatory developments, this article summarises some of the key developments within the Alzheimer’s therapeutic landscape over July.
This in-depth focus features articles on single temperature incubation, endotoxin standards and aseptic connections in pharmaceutical manufacturing.
Research predicts the global continuous bioprocessing market will witness a CAGR of 19.72 percent between 2024-2031.
Acquisition of Forge Biologics by Ajinomoto Co., Inc. is set to extend global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc.
The global biotechnology services outsourcing market is expected to reach USD 92.9 billion by 2025, according to a report by Grand View Research, Inc...
GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies...
The FDA has approved tests intended to be used as donor screening tests on samples from individual human donors, including volunteer donors of whole blood and blood components...
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
The FDA has approved Biktarvy a once-daily single-tablet regimen for the treatment of HIV-1 infection...
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
The FDA has approved Ogivri as a biosimilar to Herceptin for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene...
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
23 July 2014 | By Sucampo Pharmaceuticals, Inc
Sucampo Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA® (lubiprostone)...
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
5 September 2011 | By Gilead Sciences, Inc.
Change does not affect ongoing "All Oral" clinical trials evaluating multiple direct-acting antivirals in combination...
